Study S003211

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT07284875
Acronym: KaiNETIC-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 2530
Start: 2025-12-18
Primary completion: 2028-02
Lead sponsor: Kailera
Conditions: Obesity; Overweight
Interventions: DRUG:Ribupatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: CTIS:2025-523486-17-00; NIH:2025

Registered primary outcomes

Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76 [Baseline, Week 76]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0036322	UK patients being recruited for ribupatide trials , Pharmaceutical journal/The pharmaceutical journal	2026	Other trial	DOI	cites ClinicalTrials.gov:NCT07284875